Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression.

ABSTRACT:

Background

DNA originating from degenerate tumour cells can be detected in the circulation in many tumour types, where it can be used as a marker of disease burden as well as to monitor treatment response. Although circulating tumour DNA (ctDNA) measurement has prognostic/predictive value in metastatic prostate cancer, its utility in localised disease is unknown.

Methods

We performed whole-genome sequencing of tumour-normal pairs in eight patients with clinically localised disease undergoing prostatectomy, identifying high confidence genomic aberrations. A bespoke DNA capture and amplification panel against the highest prevalence, highest confidence aberrations for each individual was designed and used to interrogate ctDNA isolated from plasma prospectively obtained pre- and

SUBMITTER: Lau E 

PROVIDER: S-EPMC7430029 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature